TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06019949

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous spinal cord stimulator
Description: Stimulation to the spinal cord will be administered using Neostim/Biostim (Cosyma Inc., Denver CO) device by applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal cord stimulator
Description: Stimulation to the spinal cord will be administered using Neostim/Biostim (Cosyma Inc., Denver CO) device by applying up to five conductive electrodes placed on the skin at the midline over the thoracic levels as cathodes between T1 to T8, and up to four self-adhesive electrodes located symmetrically on the skin over the iliac crests and shoulders as anodes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Respiratory Training
Description: Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the respiratory training intervention.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Training
Description: Standard threshold Positive Expiratory Pressure Device (PEP, Respironics Inc., Cedar Grove, NJ) and standard threshold Inspiratory Muscle Trainer (IMT, Respironics Inc., Cedar Grove, NJ) assembled together using a T-shaped connector with a flanged mouthpiece (Airlife 001504) will be used for the respiratory training intervention.
Study: NCT06696079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Late Resumption of Oral Anticoagulation Therapy
Description: The patient's prescribed anticoagulant therapy for atrial fibrillation is resumed on the 30th postoperative day following burr-hole surgery for chronic subdural hematoma. This standard resumption strategy is compared to the early approach of resuming anticoagulation therapy on the 5th postoperative day.
Study: NCT06631573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fixed all-on-four prosthesis reinforced with PEEK framework.
Description: Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with PEEK framework.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed all-on-four prosthesis reinforced with Co-Cr framework
Description: Prosthetic rehabilitation of mandibular edentulous arches with fixed all-on-four prosthesis reinforced with Co-Cr framework
Study: NCT06629558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nitrate
Description: bronchoscopic lung volume reduction in management of localized emphysema

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nano-silver nitrate
Description: bronchoscopic lung volume reduction in management of localized emphysema

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic lung volume reduction
Description: bronchoscopic lung volume reduction in management of localized emphysema

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopic lung volume reduction
Description: bronchoscopic lung volume reduction in management of localized emphysema
Study: NCT06631196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Jacobson's PMRT
Description: each child in the intervention group will perform five sessions of Jacobson's PMRT. Each session lasted for 15-20 minutes under the supervision of the researcher.
Study: NCT06632067

Intervention type: DRUG
Intervention: sugammadex
Description: sugammadex used for neuromuscular reversal
Study: NCT04767620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rugdenzengsheng No. 1 prescription
Description: The study group was treated with the No. 1 Mammary Gland Growth Recipe orally, a total of 1 course of treatment, each course of 14 days, avoiding the menstrual period. The specific composition of Mammary Gland Hyperplasia No. 1 Recipe: Angelica 10g, Radix Paeoniae Alba 10g, Atractylodes Macrocephala 10g, Ginger 3g, Peppermint 6g, Vinegar Green Peel 6g, Lychee Seed 12g, Tangerine Seed 10g, Corydalis 10g, Fritillaria 6g, Trichosanthis 10g, Kombu 20g , Mustard seeds 10g, Moutan bark 6g, Poria 10g, North Bupleurum 6g. Method of administration: 14 doses in total, taken twice a day. The medicine is formulated in the herbal medicine room of the Affiliated Hospital of Qinghai University, with strict quality control.
Study: NCT06632067

Intervention type: DRUG
Intervention: Neostigmine + Atropine
Description: Neostigmine and Atropine used for neuromuscular reversal
Study: NCT06441331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177-Edotreotide
Description: lutetium Lu 177 edotreotide At least two cycles and a maximum of six cycles at eight-week (± 2 we-ek) intervals. Extrapolation from standard maximum adult dose of 100 Megabecquerel(MBq)/kg for a 75 kg adult for the first cohort. Dosing decision for the subsequent cohorts by Data Monitoring Committee (DMC), based on (at least) cycle 1 dosimetry and safety data from at least four participants of the preceding cohort. Route of administration: Intravenous (IV) infusion. Duration of treatment: 16-48 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amino Acid Solution
Description: The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of lysine and arginine diluted in an electrolyte solution.
Study: NCT05273307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Miraculin
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Miracle Fruit Placebo Cube
Description: Given orally
Study: NCT04996771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib,Etoposide,Cisplatin,Toripalimab
Description: In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Toripalimab 240mg,d1,q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w＋Toripalimab 240mg,d1,q3w was taken orally until the disease progressed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib,Etoposide,Cisplatin
Description: In dose escalation, Surufatinib and will be administered orally (PO) once daily (QD) ,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21，q3w+Etoposide 100mg/m2,d1-3,q3w+Cisplatin 75mg/m2 , d1, q3w,4 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21，q3w was taken orally until the disease progressed.
Study: NCT06630572

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Patients randomized to receive Rifaximin for 14 days
Study: NCT06004180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF28996
Description: Hard capsule, orally, per schedule specified in the arm description.
Study: NCT06245915

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AB-2100
Description: autologous T cell therapy
Study: NCT04482712

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Daily administration of a dose of investigational drug for up to 4 weeks while hospitalized

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of investigational drug placebo for up to 4 weeks while hospitalized
Study: NCT04962048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse-synchronized negative pressure (PSNP) device
Description: The machine consists of four components: an electrocardiograph (ECG), a vacuum pump, a software computing the timing of suction and drainage, and an individual suction cap for each patient. One leg will be treated with the PSNP-device. The treatment course with PSNP will be applied twice a day (with 4h +/- 2h in between) for two consecutive days.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control - no intervention
Description: The other leg serves as non-treated control
Study: NCT04786392

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein supplement
Description: 5 mg lutein supplement.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food, blended
Description: 5 mg lutein from baby spinach, blended.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food, unprocessed
Description: 5 mg lutein from baby spinach, in whole food form.
Study: NCT06630572

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to receive Placebo for 14 days
Study: NCT06698146

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection And Partial Liver Transplantation With Delayed Total Hepatectomy
Description: Resection And Partial Liver Transplantation With Delayed Total Hepatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection And Partial Liver Transplantation With Delayed Total Hepatectomy
Description: Resection And Partial Liver Transplantation With Delayed Total Hepatectomy
Study: NCT06705530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hem101
Description: CAR-T lymphocytes specific to CD19 B-cell antigen
Study: NCT06705023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Uncultured, autologous, adipose-derived regenerative cells (UA-ADRCs)
Description: Intracardial venous injection of fresh, uncultured, autologous, adipose-derived regenerative cells isolated from lipoaspirate at the point of care.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of patient's best guideline based medical treatment
Description: Patients will receive continuation of their best guideline based medical treatment.
Study: NCT06712212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal Hernias repair: Desarda
Description: A splitting incision is made in this sutured medial leaf, partially separating a strip 1.5-2 cm wide. This splitting incision is extended medially up to the pubic symphysis and 1-2 cm beyond the abdominal ring laterally. The medial insertion and lateral continuation of this strip is kept intact. The upper free border of the strip is now sutured to the internal oblique with number 1 Monofilament Polydioxanone Violet continuous sutures all along its length. This will result in the strip of the EOA being placed behind the cord to form a new posterior wall of the inguinal canal. The spermatic cord is placed in the inguinal canal and the lateral leaf of the EOA is sutured to the newly formed medial leaf of the EOA in front of the cord. As before, number 1 Monofilament Polydioxanone Violet continuous sutures were used. Undermining of the newly formed medial leaf on both its surfaces and excision of the bulky cremasteric muscle facilitate its approximation to the lateral leaf

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inguinal hernia repair: Darn
Description: Skin and fascia are incised using a regular, oblique inguinal incision to expose the external oblique aponeurosis (EOA) the inguinal canal is opened into by dividing the external oblique aponeurosis through the external ring. After dealing with the hernia sac, a 0-size monofilament suture was used to reconstruct the inguinal bed with a tension-free darn starting with a good strong bite of the tough tendinous structures near the pubic tubercle and emerging out through the lateral edge of the internal oblique/rectus sheath from one side and through the inguinal ligament on the other side. The loosely interwoven bites continued laterally and the back-forming two rows of continuous stitches were placed in a staggered manner to spread the tension between the fibres of the inguinal ligament. Afterwards, the external oblique and other superficial layers with the skin are classically closed
Study: NCT06712225

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Anomia therapy: semantic feature analysis and phonological components analysis;
Description: After the initial assessment + functional Magnetic Resonance Imaging (fMRI), participants will first receive their usual speech therapy rehabilitation for 10 to 15 sessions (baseline phase), and then enter the experimental phase: 18 sessions (3 per week) of either anomia therapy alone or anomia therapy + executive function training, according to the arm they were assigned to. All sessions will last 45 minutes. Naming skills will be repeatedly measured during both phases. A second assessment of language + fMRI will then be conducted and participants will return to their usual rehabilitation. Four weeks later, a final assessment of naming and discourse will be conducted.
Study: NCT06074497

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KGX101 and Envafolimab
Description: Part B combination therapy KGX101 with Envafolibmab. 400mg to be injected subcutaneously with each target dose of KGX101 every 3 weeks. The dose escalation committee (DEC) may decide to increase the dosage to 600mg. based on PK, PD and safety data.
Study: NCT06712225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anomia therapy: semantic feature analysis and phonological components analysis;
Description: After the initial assessment + functional Magnetic Resonance Imaging (fMRI), participants will first receive their usual speech therapy rehabilitation for 10 to 15 sessions (baseline phase), and then enter the experimental phase: 18 sessions (3 per week) of either anomia therapy alone or anomia therapy + executive function training, according to the arm they were assigned to. All sessions will last 45 minutes. Naming skills will be repeatedly measured during both phases. A second assessment of language + fMRI will then be conducted and participants will return to their usual rehabilitation. Four weeks later, a final assessment of naming and discourse will be conducted.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Executive function training: computerized equipment
Description: Executive function training will be conducted by means of a computerized material specifically designed for the study, consisting of verbal and nonverbal exercises targeting, always in the same order, inhibition, shifting, working memory and planning functions, with a gradient of difficulty. Training will always be done at the beginning of the session, during 20 minutes, before anomia therapy.
Study: NCT06711419

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: f caudal neuroplasty using epidural catheter combined with Pulsed Radiofrequency (PRF) versus Pulsed Radiofrequency (PRF) alone
Description: Fluoroscopic guidance was used in all cases with a C-arm system. The patient was prone with a pillow under the lower abdomen. Anteroposterior (AP) images were taken to identify the target level. The C-arm was angled 15-30° to project the spinous process over the contralateral facet (scotty dog view). Skin was infiltrated with lidocaine, and a 22-gauge RF cannula was advanced under fluoroscopy. The tip was positioned in the dorsal-cranial quadrant of the intervertebral foramen on lateral images. PRF was applied with 4 cycles at 42°C for 8 minutes after sensory/motor testing. Injections of lidocaine and triamcinolone followed. In caudal neuroplasty, an epidural catheter was placed using the sacral hiatus as a guide. Fluoroscopy confirmed catheter position. Contrast was injected to confirm spread, and hyaluronidase and lidocaine were administered. Afterward, the catheter was removed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: f caudal neuroplasty using epidural catheter combined with Pulsed Radiofrequency (PRF) versus Pulsed Radiofrequency (PRF) alone
Description: Fluoroscopic guidance was used in all cases with a C-arm system. The patient was prone with a pillow under the lower abdomen. Anteroposterior (AP) images were taken to identify the target level. The C-arm was angled 15-30° to project the spinous process over the contralateral facet (scotty dog view). Skin was infiltrated with lidocaine, and a 22-gauge RF cannula was advanced under fluoroscopy. The tip was positioned in the dorsal-cranial quadrant of the intervertebral foramen on lateral images. PRF was applied with 4 cycles at 42°C for 8 minutes after sensory/motor testing. Injections of lidocaine and triamcinolone followed. In caudal neuroplasty, an epidural catheter was placed using the sacral hiatus as a guide. Fluoroscopy confirmed catheter position. Contrast was injected to confirm spread, and hyaluronidase and lidocaine were administered. Afterward, the catheter was removed.
Study: NCT06712056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: study of focusing attention
Study: NCT06711185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Patients in this group will receive 1 tablet of 10mg dapagliflozin daily for 9 months, starting 7-10 days before chemotherapy treatment.
Study: NCT05688007

Intervention type: DIAGNOSTIC_TEST
Intervention: parathyroid hormone level
Description: Serum level of parathyroid hormone

Intervention type: DIAGNOSTIC_TEST
Intervention: parathyroid hormone level
Description: Serum level of parathyroid hormone

Intervention type: DIAGNOSTIC_TEST
Intervention: serum electrolytes
Description: Serum levels of: magnesium, phosphorus, calcium, and albumin

Intervention type: DIAGNOSTIC_TEST
Intervention: serum electrolytes
Description: Serum levels of: magnesium, phosphorus, calcium, and albumin
Study: NCT05016219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circadian-Effective Light
Description: Narrowband blue light

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Circadian-Effective Light
Description: Narrowband blue light

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Light
Description: 40 hertz (Hz) flicker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rhythmic Light
Description: 40 hertz (Hz) flicker

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Light
Description: Narrowband red light

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Light
Description: Narrowband red light

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Rhythmic Light
Description: Random flicker for placebo rhythmic effect

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Rhythmic Light
Description: Random flicker for placebo rhythmic effect
Study: NCT05226598

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab
Description: Co-formulation of pembrolizumab 200 mg/20 mL vial and vibostolimab 200 mg administered as IV infusion for up to 35 administrations
Study: NCT06711185

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group will receive 1 placebo tablet per day, with identical characteristics to the group receiving dapagliflozin, for 9 months, starting 7-10 days before the start of chemotherapy treatment
Study: NCT06236620

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Processing of wheat
Description: Investigating if the consumption of sprouted or hydrothermally processed wheat affects the iron and zinc absorption in humans

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Processing of wheat
Description: Investigating if the consumption of sprouted or hydrothermally processed wheat affects the iron and zinc absorption in humans

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Processing of wheat
Description: Investigating if the consumption of sprouted or hydrothermally processed wheat affects the iron and zinc absorption in humans
Study: NCT06714539

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient Specific Virtual Reality Stimulation
Description: A novel virtual reality (VR) simulator for spine procedures that will take patient specific medical imaging (3D scans) and create a virtual patient that surgical procedures can be performed on.
Study: NCT06712043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised Exercise
Description: An individualized exercise program consisting of aerobic exercises, strength exercises and balance exercises. The exercises will be prescribed via the Physitrack app.
Study: NCT05144841

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2140 (zilovertamab vedotin)
Description: IV infusion of 2.5 mg/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-2140 (zilovertamab vedotin)
Description: IV infusion of 2.25 mg/kg
Study: NCT05034432

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-Op Prophylactic VT ablation
Description: For surgical intra-operative ablation, efforts will be made to identify scarred myocardium based on methods such as cardiac magnetic resonance imaging, nuclear scans, and/or echocardiogram. Electrophysiological mapping may be obtained either pre-surgery or intra-operation. Mapping and ablation will be performed with the currently approved and updated mapping and ablation systems available at each center. Voltage mapping of the ventricle(s) to delineate scars will be carried out through electroanatomic mapping

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Management
Description: To ensure uniformity in control arm, a standardized AAD regimen is recommended among subjects randomized to the medical management control arm. Subjects who are already on a stable AAD regimen, such as amiodarone, sotalol or dofetilide, these should be continued
Study: NCT06431737

Intervention type: DRUG
Intervention: Amoxicillin
Description: Tegoprazan 50 mg bid, amoxicillin 1000 mg bid or 500 mg qid, clarithromycin 500 mg bid for 14 days

Intervention type: DRUG
Intervention: Amoxicillin
Description: Tegoprazan 50 mg bid, amoxicillin 1000 mg bid or 500 mg qid, clarithromycin 500 mg bid for 14 days
Study: NCT05768802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Myoelectric Implantable Recording Array (MIRA)
Description: The Myoelectric Implantable Recording Array (MIRA) will use electromyography to detect the electrical activity of forearm muscles and transmit that information to an externally-powered prosthetic limb. The MIRA is implanted under the skin.